| TERT promoter mutations |  | |
---|---|---|---|
Absent (n = 210) | Present (n = 12) | p-value | |
Age (mean years) | 45.5 ± 13.3 | 55.0 ± 11.8 | 0.017 |
Gender | Â | Â | Â |
 Female | 164 (94.8 %) | 9 (5.2 %) | 0.801 |
 Male | 46 (93.9 %) | 3 (6.1 %) | |
Tumor size (mean mm) | 14.8 ± 12.5 | 31.9 ± 22.9 | 0.043 |
Histologic types | Â | Â | Â |
 Aggressive varianta) | 18 (75.0 %) | 6 (25.0 %) | <0.001 |
 Less-aggressive variant | 192 (97.0 %) | 6 (3.0 %) | |
Pathologic T stage | Â | Â | Â |
 pT 1–2 | 97 (99.0 %) | 1 (1.0 %) | 0.014 |
 pT 3–4 | 113 (91.1 %) | 11 (8.9 %) | |
Extrathyroidal extension | Â | Â | Â |
 Absent | 105 (98.1 %) | 2 (1.9 %) | 0.035 |
 Present | 105 (91.3 %) | 10 (8.7 %) | |
Pathologic N stage | Â | Â | Â |
 pN0 | 105 (99.1 %) | 1 (0.9 %) | 0.011 |
 pN1 | 105 (91.3 %) | 10 (8.7 %) | |
Lateral lymph node metastasis | Â | Â | Â |
 Absent | 166 (98.8 %) | 2 (1.2 %) | <0.001 |
 Present | 43 (82.7 %) | 9 (17.3 %) | |
Distant metastasis | Â | Â | Â |
 Absent | 192 (100 %) | 0 | <0.001 |
 Present | 18 (60.0 %) | 12 (40 %) | |
AJCC stage | Â | Â | Â |
 I-II | 120 (100 %) | 0 | <0.001 |
 III-IV | 90 (88.2 %) | 12 (11.8 %) | |
BRAF V600E mutation | Â | Â | Â |
 Absent | 62 (95.4 %) | 3 (4.6 %) | 0.738 |
 Present | 148 (94.3 %) | 9 (5.7 %) |